secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024464
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma reports Q3 net loss of $20.2M; LIFT-AD interim analysis supports continuation
--------------------------------------------------------------------------------

- Net loss of $20.2M ($0.53/shr) for Q3 2022 vs $15.7M ($0.42) in Q3 2021; cash $260.0M at Sep 30, 2022.
- R&D expenses $17.0M (up from $10.7M YoY) driven by clinical trial and personnel costs.
- LIFT-AD interim analysis supports continuation; DMC determined <150 more patients needed for adequate power on primary endpoint.
- Expects LIFT-AD enrollment completion mid-2023; topline data early 2024.
- ACT-AD Phase 2 data showed statistically significant improvement in NfL biomarker in patients not on background therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017022024464/0000950170-22-024464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017022024464/atha-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer